Tramway Venture Partners
VC Fund
Albuquerque, United States
Tramway Venture Partners is an investment Firm.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 46%
Last updated:
For AI agents: llms.txt
Industries Tramway Venture Partners invests in
Stages Tramway Venture Partners invests in
Countries Tramway Venture Partners invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Waneta Tuttle
|
|||
Investment Focus
Industry
- Health Care 5 (38%)
- Biotechnology 5 (38%)
- Medical 4 (31%)
- Medical Device 3 (23%)
- Health Diagnostics 2 (15%)
Stage
- Series A 4 (31%)
- Seed 3 (23%)
- Series B 2 (15%)
- Funding Round 1 (8%)
- Venture - Series Unknown 1 (8%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Waneta Tuttle
Managing Partner
|
Managing Partner | Total investments: 3 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Breezy Med
|
Previously Build With Robots, Breezy Med offers hospital automation for better, faster, safer disinfection | Venture - Series Unknown / Mar 04, 2025 | |
Nob Hill Therapeutics
|
Nob Hill Therapeutics is a Delaware Corporation, founded to develop and market DryNeb, a first-in-kind dry powder nebulizer to address large pulmonary drug delivery market opportunities. The company has exclusively licensed the technology from the University of New Mexico.DryNeb™ vs. Aerosol Mist Nebulizers Compact, handheld, portable DryNeb willreplace cumbersome aerosol mist nebulizers.The pulmonary route of drug delivery has been gaining much importance in the present day, as it enables targeted drug delivery directly to the lungs for both local and systemic treatment. Pulmonary drug delivery, as a noninvasive drug administration method, is characterized by its high bioavailability and fast action. It is increasingly used in modern clinical practice for improved treatment of local as well as systemic diseases. | $3M / Series A / Aug 06, 2024 | |
Circular Genomics
|
Circular Genomics develops circular RNA (circRNA)-based diagnostic and biomarker tools for neurological and psychiatric disorders. The company uses brain-derived circRNAs, a class of stable non-coding RNA molecules enriched in the brain, to build blood-based assays that reflect disease biology in real time. Its first product, MindLight™, predictswhether a patient with major depressive disorder will respond to SSRI antidepressants. Circular Genomics is also creating additional assays designed for early detection and risk prediction of neurodegenerative diseases such as Alzheimer’s disease. The company applies its circRNA platform to help clinicians make more informed treatment decisions using molecular indicators of brain health. | $8.3M / Series A / Jan 23, 2024 | |
Vitazi.ai
|
Vitazi.ai is leading the way in Oculomics, harnessing the power of the eye to provide insights into whole-body health through our revolutionary platform, OculoInsights. | $1.9M / Seed / Dec 01, 2022 | |
|
Circular Genomics
|
Circular Genomics develops circular RNA (circRNA)-based diagnostic and biomarker tools for neurological and psychiatric disorders. The company uses brain-derived circRNAs, a class of stable non-coding RNA molecules enriched in the brain, to build blood-based assays that reflect disease biology in real time. Its first product, MindLight™, predictswhether a patient with major depressive disorder will respond to SSRI antidepressants. Circular Genomics is also creating additional assays designed for early detection and risk prediction of neurodegenerative diseases such as Alzheimer’s disease. The company applies its circRNA platform to help clinicians make more informed treatment decisions using molecular indicators of brain health. | $4.5M / Seed / Dec 14, 2021 | |
Daisy Genomics
|
Armonica Technologies derives its name from prolific innovator Benjamin Franklin’s favorite invention, The Glass Armonica. Armonica Technologies is an early stage medtech company focused on developing its proprietary long-read DNA sequencing technology for precision medicine applications. The Company’s technology is based upon a portfolio ofpatented and patent pending technologies licensed from STC.UNM. | $2M / Series B / Oct 18, 2021 | |
WaveDyn Vision
|
WaveDyn Vision is an early-stage medical device company with innovative wavefront diagnostic technology for use in the vision care industry. It plans to leverage its proprietary dynamic wavefront measurement technology to yield new insights into assessing visual performance, advancing treatment options, and improving the quality of life for thevisually impaired.The company was founded in 2019 and is based in Albuquerque, New Mexico. | $2M / Aug 26, 2020 | |
|
WaveDyn Vision
|
WaveDyn Vision is an early-stage medical device company with innovative wavefront diagnostic technology for use in the vision care industry. It plans to leverage its proprietary dynamic wavefront measurement technology to yield new insights into assessing visual performance, advancing treatment options, and improving the quality of life for thevisually impaired.The company was founded in 2019 and is based in Albuquerque, New Mexico. | $2M / Series A / Aug 26, 2020 | |
WaveFront Dynamics
|
WaveFront Dynamics is a medical device company with innovative wavefront diagnostic technology for use in the vision care industry. | Series A / Aug 25, 2020 | |
BennuBio
|
BennuBio is developing instruments that can use the flow cytometry paradigm to analyze samples regardless of particle size or sample volume. The company is an emerging technology company delivering unique cell analysis systems. BennuBio was founded in 2018 and based in Albuquerque, New Mexico. | $5M / Series B / Apr 01, 2020 | |
| See all 13 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Tramway Venture Partners invest in?
Tramway Venture Partners invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Seed stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Tramway Venture Partners?
Public channels for Tramway Venture Partners include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Tramway Venture Partners?
The team at Tramway Venture Partners includes Waneta Tuttle (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
